1. Home
  2. NTLA

NTLA

Intellia Therapeutics Inc.

Logo Intellia Therapeutics Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Founded: 2014 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 2.1B IPO Year: 2016
Target Price: $70.62 AVG Volume (30 days): 1.6M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.42 EPS Growth: N/A
52 Week Low/High: $22.67 - $47.48 Next Earning Date: 05-02-2024
Revenue: $36,275,000 Revenue Growth: -30.40%
Revenue Growth (this year): 42.61% Revenue Growth (next year): 7.92%

Share on Social Networks:

Stock Insider Trading Activity of Intellia Therapeutics Inc. (NTLA)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
BASTA JAMES NTLA EVP, General Counsel Mar 1 '24 Sell $32.99 2,297 $75,778.03 81,571 SEC Form 4
Clark Eliana NTLA EVP, Chief Technical Officer Jan 3 '24 Sell $29.46 4,301 $126,707.46 40,845 SEC Form 4
Clark Eliana NTLA EVP, Chief Technical Officer Jan 3 '24 Sell $30.12 307 $9,246.84 45,146 SEC Form 4
Lebwohl David NTLA EVP, Chief Medical Officer Jan 3 '24 Sell $29.46 5,843 $172,134.78 54,372 SEC Form 4